Tufts CSDD data shows no outsourcing model wins on speed or quality. Executive Director Ken Getz explains what matters more.
- What Happens When Acquisition Due Diligence Ignores Clinical Operations?
- Who's Wearing The Patient Recruitment Hat When Your Trial Decisions Are Made?
- Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
- Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
- Two Parallel Trials, A Potential New Option For Protection From COVID-19
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
GUEST COLUMNISTS
-
Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
Incannex CEO Joel Latham explains how thoughtful trial design and dose optimization can turn promising data into an approval-ready strategy.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
CLINICAL TRIAL WHITE PAPERS
-
The Next Era Of eCOA Is AI
Discover how AI is moving beyond the hype to streamline clinical study builds. Explore practical ways to automate protocol digitization and UAT scripts while preparing for future patient tools.
-
Proving The Return On Investment For eRegulatory1/22/2025
Explore a study of how leading research centers, CROs, and sponsors cover the cost of eRegulatory tools … and then some.
-
Navigating The European Market's Regulatory Complexities12/30/2024
Prepare your EU launch strategy with this comprehensive guide detailing what is needed to ensure compliance and efficiency in the EU market.
-
Connected Trial Execution: Why Integrating IRT, eCOA And Clinical Supply Matters More Than Ever9/16/2026
Many sponsors are still managing IRT, eCOA, and Clinical Supply for complex trials as separate functions, creating unnecessary risk. Explore what is needed to integrate these workflows safely.
-
Reducing Inventory Errors In Clinical Trials5/8/2026
Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.
-
Immunohistochemistry In Precision Medicine: From Biomarker To Clinical Trial Assay6/17/2025
From preclinical validation to clinical implementation, immunohistochemistry (IHC) is essential in understanding target biology and ensuring drug safety and efficacy.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Accelerating The Path To Clinical Proof-Of-Concept11/17/2026
Discover how Altasciences' integrated strategy helped a biotech advance its incretin-based injectable from safety assessment to proof-of-concept in approximately 22 months.
-
Rescuing A Global Full-Service Phase III Trial For A Late-Stage Oncology Biotech10/2/2025
This case underscores the expertise employed in a comprehensive strategy and set of services that were used to salvage a Phase III clinical trial for ovarian cancer and ensure its timely completion.
-
Use Of Epiontis ID In A Phase 2 Psoriasis Trial9/25/2025
Mirikizumab’s Phase 2 trial explores IL-23 inhibition in psoriasis, measuring immune cell changes to assess its potential for long-term disease control and flare-up prevention.
-
Solutions To The Challenges Of Oncology Trials5/6/2025
This significant Phase III trial, one of the largest global studies in head and neck cancer, faced considerable challenges including enrollment delays and an intricate study design.
-
Tailored Approach Supports Bladder Cancer Breakthrough3/5/2026
Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.
-
Expanding Clinical Research In East Africa With Digital Innovation12/11/2025
Africa carries 25% of the world’s disease burden but hosts only 1% of clinical trials. Discover technology-driven strategies that close this gap and transform research access in underserved regions.
NEWSLETTER ARCHIVE
- 11.20.26 -- Oversight Monitoring In Clinical Trials
- 11.20.26 -- Overloaded Sites, Stalled Enrollment, Lost Patients: Where Trial Execution Breaks Down
- 11.19.26 -- A New Era For Clinical Development For Brazil
- 11.18.26 -- Lab Logistics: Delivering The Complex Without Compromise
- 11.18.26 -- Sponsors Can Drown In Data As Patient Diversity Gaps Persist
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Recruitment problems can start long before actual recruitment. Who is making sure your team gets ahead of those challenges?
-
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
FOCUS ON PATIENTS
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
-
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
EDITORIAL COLLECTIONS
Take a deep dive into the issues shaping clinical research today with our curated Editorial Collections. Each collection features expert insights and practical strategies addressing today’s biggest challenges in clinical trial planning and execution.
More Editorial Collections
